Determining risk factors for the development of psoriatic arthritis (PsA) amongst people living with psoriasis: A patient-driven online prospective European observational cohort

Determining risk factors for the development of psoriatic arthritis (PsA) amongst people living with psoriasis: A patient-driven online prospective European observational cohort - HIPPOCRATES Prospective Observational Study (HPOS)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON57419

Enrollment

1000

Registered

2024-03-08

Start date

2025-10-29

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

psoriasis psoriatic arthritis psoriasis psoriatic arthritis

Interventions

nvt

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adults with psoriasis

Exclusion criteria

Exclusion criteria: Pre-existing diagnosis of psoriatic arthritis

Design outcomes

Primary

Measure	Time frame
To identify demographic, clinical and biological predictors for the development of PsA: Development of PsA confirmed by upload of clinic letter confirming diagnosis.	—

Secondary

Measure	Time frame
To test the performance of the PEST screening questionnaire in identifying PsA: Development of PsA confirmed by upload of clinic letter confirming diagnosis. To establish the burden of psoriasis across Europe: Patient reported outcomes including PsA impact of disease (PsAID), Multi-dimensional health assessment questionnaire (MD-HAQ), Patient health questionnaire (PHQ-9), FACIT-fatigue. To establish the burden of psoriasis treatment across Europe: Treatment satisfaction questionnaire for medication (TSQM).	—

Measure

Time frame

To test the performance of the PEST screening questionnaire in identifying PsA: Development of PsA confirmed by upload of clinic letter confirming diagnosis. To establish the burden of psoriasis across Europe: Patient reported outcomes including PsA impact of disease (PsAID), Multi-dimensional health assessment questionnaire (MD-HAQ), Patient health questionnaire (PHQ-9), FACIT-fatigue. To establish the burden of psoriasis treatment across Europe: Treatment satisfaction questionnaire for medication (TSQM).

—

Countries

Czech Republic, Germany, Greece, Ireland, Netherlands, Norway, Poland, Portugal, Romania, United Kingdom

Contacts

Public ContactM.G.H. Sande

Amsterdam UMC

m.g.vandesande@amsterdamumc.nl020-5662694

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026